Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc.

NBIX

Market Cap$10.03B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Neurocrine Biosciences, Inc.Neurocrine Biosciences, Inc.29.8-13%4.40.2
$156.00

Target Price by Analysts

54.9% upsideNeurocrine Biosciences Target Price DetailsTarget Price
$267.93

Current Fair Value

166.1% upside

Undervalued by 166.1% based on the discounted cash flow analysis.

Share Statistics

Market cap$10.03 Billion
Enterprise Value$10.25 Billion
Dividend Yield$0 (0%)
Earnings per Share$3.4
Beta0.33
Outstanding Shares100,400,000

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio29.82
PEG-98.76
Price to Sales4.38
Price to Book Ratio4.03
Enterprise Value to Revenue4.35
Enterprise Value to EBIT17.69
Enterprise Value to Net Income30
Total Debt to Enterprise0.04
Debt to Equity0.18

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Neurocrine Biosciences, Inc.

CEO: Kevin Gorman